β 2 -microglobulin (β 2 m) and anti-β 2 m...

Details β 2 -microglobulin (β 2 m) and anti-β 2 m... β 2 -microglobulin (β 2 m) and anti-β 2 m...

2003-04-10

2008-03-11

Yu, Misook (Department: 1642)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

C424S174100

Reexamination Certificate

active

07341721

ABSTRACT:
The present invention describes the use of agents that interact with major histocompatibility complex (MHC) HLA class I molecules, such as β2-microglobulin, or antibodies that bind to β2-microglobulin, for the treatment and prevention of multiple myeloma and other types of cancer. The anti-cancer therapeutics of the present invention interact with MHC molecules on the surface of the tumor cell to increase apoptosis and inhibit cell growth and proliferation. For example, in an embodiment, anti-β2-microglobulin antibodies inhibit the growth of multiple myeloma cells by over 90%. Thus, the present invention describes a new class of anti-cancer therapeutics and methods of use.

REFERENCES:
Freshney (Culture of Animal Cells, A Manual of Basic Technique, Alan R. Liss, Inc., 1983, New York, p. 4).
Dermer (Bio/Technology, 1994, 12:320).
Gura (Science, 1997, 278:1041-1042.).
Jain (Scientific American Jul. 1994).
Dillman (Annals of Internal Medicine, vol. 111, pp. 592-603, 1989).
Weiner (Seminars Oncology, vol. 26, No. 4, 1999, pp. 41-50).
Durie et al (Blood, 1990, 75(4):823-830).
Alexanian, R. et al., The Treatment of Multiple Myeloma,New England Journal of Medicine, 330, 484-489, 1994.
Barlogie, B., Plasma Cell Myeloma, In: E. Beutler, M. Lichtman, B. Coller, and T. Kipps, (eds.) InWilliam's Hematology, Fifth Edition, New York: McGraw-Hill, 1109-1126, 1995.
Barlogie, B. et al., Total Therapy with Tandem Transplants for Newly Diagnosed Multiple Myeloma,Blood, 93, 55-65, 1999.
Bataille, R. et al., Beta-2-Microglobulin in Myeloma: Optimal Use for Staging, Prognosis, and Treatment—a Prospective Study of 160 Patients,Blood, 63, 468-476, 1984.
Bataille, R. et al., In Vitro Production of Beta-2-Microglobulin by Human Myeloma Cells,Cancer Investigation, 6, 271-277, 1988.
Bjorkman, P. J. et al., Structure, Function and Diversity of Class I Major Histocompatibility Molecules,Annual Review of Biochemistry, 59, 253-288, 1990.
Blackman, M. et al., The Role of the T Cell Receptor in Positive and Negative Selection of Developing T Cells,Science, 248, 1335-1341, 1990.
Bratton, S. B. et al., Protein Complexes Activate Distinct Cascades in Death Receptor and Stress-Induced Apoptosis,Experimental Cell Research, 256, 27-33, 2000.
Brenning, G. et al., The Effect of Alpha and Gamma-Interferon on Proliferation and Production of IgE and beta 2-microglobulin in the Human Myeloma Cell Line U266 and in an Alpha-Interferon resistant U266 Subline,Sandinavian Journal of Haematology, 37, 280-288, 1986.
Bunning, R. A. et al., Serum β2-Microglobulin Levels in Urological Cancer,Journal of Urology, 121, 624-625, 1979.
Campos, L. et al., Serum β2-Microglobulin in Adult Myeloid Acute Leukemias,Blut, 48, 221-226, 1984.
Cuzik, J. et al., The Prognostic Value of Serum β2-Microglobulin Compared with Other Presentation Features in Myelomatosis,British Journal of Cancer, 52, 1-6, 1985.
Demaria, S. et al., CD8 and β2-Microglobulin-Free MHC Class I Molecules in T Cell Immunoregulation,International Journal of Clinical and Laboratory Research, 23, 61-69, 1993.
Genestier, L. et al., T Cell Sensitivity to HLA Class I-Mediated Apoptosis Is Dependent on Interleukin-2 and Interleukin-4,European Journal of Immunology, 27, 495-499, 1997.
Georgii-Hemming et al., Insulin-Like Growth Factor I Is a Growth and Survival Factor in Human Multiple Myeloma Cell Lines,Blood, 88, 2250-2258, 1996.
Gratzner, H. G., Monoclonal Antibody to 5-Bromo- and 5-Iododeoxyuridine: a New Reagent for Detection of DNA Replication,Science, 218, 474-475, 1982.
Grieco, M. H. et al., Elevated β2-Microglobulin and Lysozyme Levels in Patients with Acquired Immune Deficiency Syndrome,Clinical Immunology and Immunopathology, 32, 174-184, 1984.
Grigorieva, I. et al., The Bone Marrow Stromal Environment Is a Major Factor in Myeloma Cell Resistance to Dexamethasone,Experimental Hematology, 26, 597-603, 1998.
Hallek, M. et al., Multiple Myeloma: Increasing Evidence for a Multistep Transformation Process,Blood, 91, 3-21, 1998.
Hardin, J. et al., Interleukin-6 Prevents Desamethasone-Induced Myeloma Cell Death,Blood, 84, 3063-3070, 1994.
Hyafil, F. et al., Dissociation and Exchange of the Beta2-Microglobulin Subunit of HLA-A and HLA-B Antigens,Proceeding of the National Academy of Sciences USA, 76, 5834-5838, 1979.
Karlsson, F. A. et al., β2-Microglobulin in Clinical Medicine,Scandinavian Journal of Clinical and Laboratory Investigation, 40, S27-S37, 1980.
Kawano, M. et al., Autocrine Generation and Requirement of BSF-2/IL-6 for Human Multiple Myeloma,Nature, 332, 83-85, 1988.
Kuby, J., Major Histocompatibility Complex, In: J. Kuby (ed.),Immunology, Third Edition, New York: W. H. Freeman, 223-262, 1997.
Ladasky, J. J. et al., Residue 3 of β2-Microglobulin Affects Binding of Class I MHC Molecules by the W6/32 Antibody,Immunogenetics, 49, 312-320, 1999.
Liabeuf, A. et al., An Antigenic Determinant of Human β2-Microglobulin Masked by the Association with HLA Heavy Chains at the Cell Surface: Analysis Using Monoclonal Antibodies,Journal of Immunology, 127, 1542-1548, 1981.
Lifson, A. R. et al., Serum β2-Microglobulin and Prediction of Progression to AIDS in HIV Infection,Lancet, 339, 1436-1440, 1992.
Ljunggren, H. G et al., In Search of the “Missing Self”: MHC Molecules and NK Cell Recognition,Immunol. Today, 11, 237-244, 1990.
Menaa, C. et al., Tumor Necrosis Factor Mediates the Stimulatory Effect of β2-Microglobulin on Osteoclast Formation,American Society for Bone and Mineral Research, 23rdMeeting Abstract Book, p. 17 (absr), 2001.
Min, R. et al., β2-Microglobulin as a Negative Growth Regulator of Myeloma Cells,British Journal of Haematology, 118, 495-505, 2002.
Mori, M. et al., β2-Microglobulin Identified as an Apoptosis-Inducing Factor and Its Characterization,Blood, 94, 2744-2753, 1999.
Mori, M., Antitumor Effect of β2-Microglobulin in Leukemic Cell-Bearing Mice via Apoptosis-Inducing Activity: Activation of Caspase-3 and Nuclear Factor-κB1Cancer Res., 61, 4414-4417, 2001.
Parker, K. C. et al., Subunit Interactions of Class I Histocompatibility Antigens,Biochemistry, 24, 5543-5550, 1985.
Revillard, J. P. et al., Structure and Metabolism of β2-Microglobulin.Contribution in Nephrology, 62, 44-53, 1988.
Revillard, J. P. et al., β2-Microglobulin and β2-Microglobulin-Binding Proteins in Inflammatory Diseases,European Journal of Rheumatology and Inflammation, 5, 398-405, 1982.
Rock, K. L. et al., Dissociation of β2-Microglobulin Leads to the Accumulation of a Substantial Pool of Inactive Class I MHC Heavy Chains on the Cell Surface,Cell, 65, 611-620, 1991.
Schardijn, G. H. et al., β2-Microglobulin: Its Significance in the Evaluation of Renal Function,Kidney International, 32, 635-641, 1987.
Skov, S., Intracellular Signal Transduction Mediated by Ligation of MHC Class I Molecules,Tissue Antigens, 51, 215-223, 1998.
Skov, S. et al., Ligation of Major Histocompatability Complex (MHC) Class I Molecules on Human T Cells Induces Cell Death through PI-3 Kinase-Induced c-Jun NH2-Terminal Kinase Activity: a Novel Apoptotic Pathway Distinct from Fas-Induced Apoptosis,Journal of Cell Biology, 139, 1523-1531, 1997.
Smith, M. H. et al., The Conformational Flexibility of Class I H-2 Molecules as Revealed by Anti-Peptide Antibodies Specific for Intracytoplasmic Determinants: Differential reactivity of β2-Microglobulin “Bound” and “Free” H2Kb Heavy chains,Molecular Immunology, 27, 169-180, 1990.
Sprague, S. M. et al., Is β2-Microglobulin a Mediator of Bone Disease?Kidney Int., 47, 1-6, 1995.
Townsend, A. R. et al., Antigen Recognition by Class I—Restricted T Lymphocytes,Annua. Review of Immunology, 7, 601-624, 1989.
Vermes, I. et al., A Novel Assay for Apoptosis: Flow Cytometric Detection of Phosphatidylserine Expression on Early Apoptotic Cells Using Fluorescein Labeled Annexin V.,Journal of Immunological Methods, 184, 39-51, 1995.
Walters, M. T. et al., Comparison of Serum and Synovial Fluid Concentr

Affiliated with

Also associated with

Rating

β 2 -microglobulin (β 2 m) and anti-β 2 m... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with β 2 -microglobulin (β 2 m) and anti-β 2 m..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and β 2 -microglobulin (β 2 m) and anti-β 2 m... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3960219